PTGX250117C35000
- 4.10
- -0.35-7.87%
Protagonist Therapeutics Newsroom
JMP Securities Maintains Protagonist Therapeutics(PTGX.US) With Buy Rating, Maintains Target Price $58
BTIG Upgrades Protagonist Therapeutics(PTGX.US) to Buy Rating, Maintains Target Price $67
JMP Securities Maintains Protagonist Therapeutics(PTGX.US) With Buy Rating, Maintains Target Price $58
Optimistic Buy Rating for Protagonist Therapeutics Driven by Promising Rusfertide Data and Strategic Takeda Partnership
H.C. Wainwright Maintains Protagonist Therapeutics(PTGX.US) With Buy Rating, Maintains Target Price $50
Wedbush Maintains Protagonist Therapeutics(PTGX.US) With Buy Rating, Maintains Target Price $58
J.P. Morgan Maintains Protagonist Therapeutics(PTGX.US) With Buy Rating
Analysts Are Bullish on Top Healthcare Stocks: AbbVie (ABBV), Protagonist Therapeutics (PTGX)
Protagonist Therapeutics Initiated at Outperform by BMO Capital
Protagonist Therapeutics Analyst Ratings
Goldman Sachs Initiates Protagonist Therapeutics(PTGX.US) With Hold Rating, Announces Target Price $47
BMO Capital Initiates Protagonist Therapeutics(PTGX.US) With Buy Rating, Announces Target Price $62
Buy Rating Affirmed for Protagonist Therapeutics: Innovative Peptide Platform and Promising Pipeline Drive Growth Prospects
JMP Securities Maintains Protagonist Therapeutics(PTGX.US) With Buy Rating, Raises Target Price to $58
Truist Financial Maintains Protagonist Therapeutics(PTGX.US) With Buy Rating
BTIG Downgrades Protagonist Therapeutics(PTGX.US) to Hold Rating, Raises Target Price to $67
Wedbush Maintains Protagonist Therapeutics(PTGX.US) With Buy Rating, Maintains Target Price $58
Protagonist Therapeutics Price Target Maintained With a $50.00/Share by HC Wainwright & Co.
TD Cowen Maintains Protagonist Therapeutics(PTGX.US) With Buy Rating, Maintains Target Price $65
A Quick Look at Today's Ratings for Protagonist Therapeutics(PTGX.US), With a Forecast Between $50 to $65